Escitalopram in Asthma Patients With Frequent Exacerbation

Eligibility Criteria

• * Moderate to severe persistent asthma
• * Treatment with medium to high dose ICS and LABA therapy
• * Three or more severe asthma exacerbations (requiring ≥ 3 days of systemic corticosteroids) in the past year
• * Age 18-65 years old, male or female sex, English or Spanish speaking
• * Participants will be required to be clinically stable with no recent exacerbations, infections or changes in asthma controller therapy for at least 4 weeks before study entry
• * Biologic therapy for asthma (e.g., omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab) will be allowed if started at least 6 months prior to randomization
• * Current substance use disorder and/or current tobacco use or greater than 10 pack-years lifetime use
• * A current MDD episode as well as bipolar disorder, schizophrenia, or schizoaffective disorder
• * Vulnerable populations including intellectual disability or other severe cognitive impairment, inmates, pregnant or nursing women or women of childbearing age who will not use UT Southwestern IRB-approved methods of birth control or abstinence during the study
• * Currently taking an antidepressant (antidepressants that are not SSRIs nor SNRIs prescribed for an indication other than depression at subtherapeutic doses are acceptable)
• * High risk for suicide defined as \> 1 past suicide attempts or any attempt within the past 12 months
• * Severe or life-threatening medical illness that would make completion of study unlikely or clinically significant laboratory or ECG findings at baseline